Pattern of failure, impact of local therapy, and characteristics of long-term responders with advanced EGFR mutation positive non-small cell lung cancer treated with first-line osimertinib.

Chen ACC, Mok FST, Wong WKY, Lam BHW, Johnson D, Lee MMP, Chan LL, Mo F, Mok KKS, Chen OH, Lee KWC, Loong HHF, Lam KC, Yan K, Mok TSK, Li MSC.

Open source

DOI
10.1016/j.lungcan.2025.108808
Published
2025-11-01
Container
Lung Cancer
Publisher
Not recorded
Open access
no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/j.lungcan.2025.108808,
  title = {Pattern of failure, impact of local therapy, and characteristics of long-term responders with advanced EGFR mutation positive non-small cell lung cancer treated with first-line osimertinib.},
  author = {Chen ACC and  Mok FST and  Wong WKY and  Lam BHW and  Johnson D and  Lee MMP and  Chan LL and  Mo F and  Mok KKS and  Chen OH and  Lee KWC and  Loong HHF and  Lam KC and  Yan K and  Mok TSK and  Li MSC.},
  year = {2025},
  journal = {Lung Cancer},
  doi = {10.1016/j.lungcan.2025.108808},
  url = {https://doi.org/10.1016/j.lungcan.2025.108808}
}

RIS

TY  - JOUR
TI  - Pattern of failure, impact of local therapy, and characteristics of long-term responders with advanced EGFR mutation positive non-small cell lung cancer treated with first-line osimertinib.
AU  - Chen ACC
AU  -  Mok FST
AU  -  Wong WKY
AU  -  Lam BHW
AU  -  Johnson D
AU  -  Lee MMP
AU  -  Chan LL
AU  -  Mo F
AU  -  Mok KKS
AU  -  Chen OH
AU  -  Lee KWC
AU  -  Loong HHF
AU  -  Lam KC
AU  -  Yan K
AU  -  Mok TSK
AU  -  Li MSC.
PY  - 2025
JO  - Lung Cancer
DO  - 10.1016/j.lungcan.2025.108808
UR  - https://doi.org/10.1016/j.lungcan.2025.108808
ER  - 

APA

ACC, C., FST, M., WKY, W., BHW, L., D, J., MMP, L., LL, C., F, M., KKS, M., OH, C., KWC, L., HHF, L., KC, L., K, Y., TSK, M., & MSC., L. (2025). Pattern of failure, impact of local therapy, and characteristics of long-term responders with advanced EGFR mutation positive non-small cell lung cancer treated with first-line osimertinib.. Lung Cancer. https://doi.org/10.1016/j.lungcan.2025.108808

Source records